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1. Introduction
The global spread of carbapenem-resistant Acinetobacter
baumannii (CRAB) has been observed and is considered a sentinel
event of emerging antimicrobial resistance.1 In an extensive
survey, the European clone II (ECII) clonal complex was found to be
the most widespread clone of clinical CRAB isolates on ﬁve
continents.1 Reports describing CRAB dissemination in the African
continent are scarce and the studies have been limited to northern
and southern regions of Africa.1,2
Carbapenem resistance mechanisms in A. baumannii are more
commonly mediated by carbapenem-hydrolyzing class D b-
lactamases (CHDLs) and less often by class B metallo-b-lactamases
(MBLs).2 To our knowledge, several CHDLs (OXA-23, OXA-24, OXA-
58, and OXA-97) and a few MBLs (GES and NDM-1) have been
identiﬁed so far in clinical A. baumannii isolates in Africa.3 OXA-23-
producing CRAB has been reported from African countries
including Algeria, Tunisia, Libya, Egypt, Senegal, Nigeria, South
Africa, and Madagascar. The acquisition of the blaOXA-23 gene has
been associated with four genetic structures that consist of diverse
conjunctions with insertion sequences ISAba1 and ISAba4, and all
of these structures have been identiﬁed in Tunisia, Algeria, Libya,
and South Africa.2,3
Before 2008, A. baumannii was uncommon among pathogens
recovered at Aga Khan University Hospital, Kenya, and it had
remained susceptible to several antibiotics including extended-
spectrum cephalosporins, carbapenems, and aminoglycosides.
CRAB appeared in 2009 and caused an outbreak in an intensive
care unit that lasted for 5 months before being controlled by strict
and sustained infection control measures. During the same period,
clonally-related New Delhi metallo-b-lactamase 1 (NDM-1)-
producing Klebsiella pneumoniae isolates were identiﬁed in our
hospital and were found to carry various genes encoding b-lactam
and aminoglycoside resistance.4 In the present study, we
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S U M M A R Y
Background: The emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) was observed in a
Kenyan hospital from 2009 to 2010. Further investigation of the dissemination of CRAB isolates and the
molecular characterization of associated resistance determinants were therefore performed.
Methods: Antibiotic susceptibilities were determined by broth microdilution and Etest. Metallo-b-
lactamases were detected by Etest method. Clonal relationships were studied by pulsed-ﬁeld gel
electrophoresis (PFGE) and multilocus sequence typing (MLST). b-Lactam and aminoglycoside
resistance determinants and the clonal relatedness to widespread European clones were studied by
PCR and sequencing.
Results: Sixteen CRAB isolates from 10 patients possessed six pulsotypes; half of the isolates belonged to
the European clone II (ECII) lineage. ECII strains were typed as MLST sequence type 2 (ST2) and ST109,
and non-ECII strains as ST25 and ST113. All isolates harbored ISAba1–blaOXA-23, blaOXA-51-like, blaADC, and
class 1 integron, including one that also harbored blaNDM-1. ADC-57 and two integron cassettes (arr-2-
cmlA5 and aadB-aadA2-cmlA6-aadA15) were newly-identiﬁed. Non-ECII isolates, designated non-ECII
clone, carried armA and integron cassette arr-2-cmlA5.
Conclusions: Two distinct clones of CRAB – ECII and non-ECII epidemic clones – were disseminated in
Kenya. The concomitance of ISAba1–blaOXA-23 was the major mechanism contributing to CRAB. The ﬁrst
identiﬁcation of ECII CRAB and New Delhi metallo-b-lactamase 1 (NDM-1) extensively drug-resistant A.
baumannii in East Africa is of concern.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
* Corresponding author. Tel.: +886 37 246 166; fax: +886 37 586 457.
E-mail address: mimicry@nhri.org.tw (L.-Y. Huang).
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investigated clonal dissemination and mechanisms of resistance to
carbapenem and aminoglycosides in CRAB isolates.
2. Methods
2.1. Isolates and antimicrobial susceptibility testing
CRAB isolates were collected in Aga Khan University Hospital, a
250-bed tertiary care facility, from January 2009 to August 2010.
Among the 16 isolates, 10 were from seven Kenyan patients, three
were from two Rwandan patients, and three were from a
Tanzanian patient. The isolates were initially identiﬁed by
API 20E and conﬁrmed using the Vitek system (Vitek AMS;
bioMe´rieux Vitek Systems Inc., Hazelwood, MO, USA); further
species identiﬁcation was done by multiplex PCR and recA
sequencing.5
The minimum inhibitory concentrations (MICs) were deter-
mined by broth microdilution method with Sensititre plates (TREK
Diagnostic Systems, West Sussex, UK), except the MICs of
imipenem, which were determined with MBL Etest strips (AB
Biodisk, Solna, Sweden), and interpreted in accordance with the
Clinical and Laboratory Standards Institute (CLSI) guidelines.6 The
antimicrobial agents tested using broth microdilution included
ampicillin, ampicillin/sulbactam, piperacillin, piperacillin/tazo-
bactam, cefazolin, ceftazidime, ceftriaxone, cefepime, cefmetazole,
meropenem, ciproﬂoxacin, levoﬂoxacin, gentamicin, amikacin,
tigecycline, and trimethoprim/sulfamethoxazole. Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as
quality control strains.
2.2. Molecular typing and PCR assays
All isolates were typed by pulsed-ﬁeld gel electrophoresis
(PFGE) and multilocus sequence typing (MLST).5,7
b-Lactamase genes (blaKPC, blaIMP, blaVIM, blaGIM, blaSPM, blaSIM,
blaOXA-23-like, blaOXA-24/OXA-40-like, blaOXA-51-like, blaOXA-58-like and
blaADC), amikacin resistance genes (armA, rmtA, rmtB, rmtC, rmtD,
aac(60)-Iad, aac(60)-Ib, aac(60)-Ih and aph(30)-VI), the relative
genetic mobile elements (intI1, intI2, intI3, ISAba1, and ISAba4),
the variable regions of class 1 integrons, and clonality (European
clones I, II, III) were investigated by PCR, and the amplicons were
sequenced as described previously.5,8–10 blaNDM was detected with
the primers ATGGAATTGCCCAATATTATGC and CGAAAGT-
CAGGCTGTGTTG. The full-length of the blaNDM, blaADC, and
blaOXA-23 genes were sought with primer pairs NDM ATG-
GAATTGCCCAATATTATGC and TCAGCGCAGCTTGTCGG, ADC ATGC-
GATTTAAAAAAATTTCTTGTC and TTATTTCTTTATTGCATTCAGCAC,
and OXA23 TTATTTTCTATTGATCTGGTGTTT and TAGAGTTTCTGT-
CAAGC, respectively.
2.3. Nucleotide accession numbers
The sequences of the variable regions of the integrons of
representative isolates 5 and 14 have been deposited in GenBank
under the accession numbers HQ141279 and HQ148722, respec-
tively. The nucleotide sequence of the novel ADC-57 enzyme has
been assigned the accession number HQ258925.
3. Results
3.1. Isolation and clonal relatedness of collected isolates
Among 16 isolates, 10 (55.6%) were obtained from tracheal
aspirate; the others were from bone marrow aspirate, cerebrospi-
nal ﬂuid, catheter tip, axillary swab, nasal swab, urine, blood, and
debrided tissue samples. Six pulsotypes were identiﬁed among
these isolates and were determined to be non-clonally related.
Eight isolates (50%) belonging to the pulsotypes III, V, VI, were
found to be afﬁliated with ECII lineages. MLST analysis revealed
four sequence types (ST). Among eight ECII strains, seven belonged
to ST2 (2-2-2-2-2-2-2) and one to ST109 (26-4-2-2-9-1-5). In the
other eight non-ECII strains, six belonged to ST25 (3-3-2-4-7-2-4)
and two to ST113 (3-3-3-4-7-4-4) (Table 1).
3.2. Antimicrobial susceptibility
All CRAB isolates were resistant to b-lactams, with the
exception of one cefepime-intermediate isolate. With respect to
ﬂuoroquinolone antibiotics, there was a higher resistance rate to
ciproﬂoxacin (100%) than to levoﬂoxacin (43.8%). With regard to
Table 1
Characteristics of carbapenem-resistant Acinetobacter baumannii isolates






















1 512 + (NDM-1) +  (OXA-64) 64 + (ArmA) + (Aac(60)-Ih, Aph(30)-VI) 64  (ADC-26) - 25 I
2 16 - +  (OXA-64) 64 + (ArmA)  64  (ADC-26) - 25 I
3 16 - +  (OXA-64) 64 + (ArmA)  64  (ADC-26) - 25 I
4 16 - +  (OXA-64) 64 + (ArmA)  64  (ADC-26) - 25 II
5 32 - +  (OXA-64) 64 + (ArmA)  64  (ADC-26) - 25 II
6 32 - +  (OXA-64) 64 + (ArmA)  64  (ADC-26) - 25 II
7 32 - + + (OXA-66) 2   64 + (ADC-30) II 2 III
8 64 - + + (OXA-66) 2   64 + (ADC-30) II 2 III
9 16 - + + (OXA-66) 2   64 + (ADC-30) II 2 IIIa
10 32 - + + (OXA-66) 2   64 + (ADC-30) II 2 IIIb
11 32 - + + (OXA-66) 2   64 + (ADC-30) II 2 IIIb
12 64 - +  (OXA-64) 4 + (ArmA)  64  (ADC-57) - 113 IV
13 64 - +  (OXA-64) 4 + (ArmA)  64  (ADC-57) - 113 IVa
14 16 - +  (OXA-67) 2   64  (ADC-26) II 109 V
15 16 - +  (OXA-66) 16  + (Aph(30)-VI) 64 + (ADC-30) II 2 VI
16 32 - +  (OXA-66) 32  + (Aph(30)-VI) 64 + (ADC-30) II 2 IIIa
MIC, minimum inhibitory concentration; IPM, imipenem; AMK, amikacin; CAZ, ceftazidime; MBL, metallo-b-lactamase; AME, aminoglycoside-modifying enzyme; ST,
sequence type.
a The screened MBL genes included blaIMP-like, blaVIM-like, blaSIM, blaGIM, blaSPM, and blaNDM.
b The screened AME genes included amikacin resistance genes aac(60)-Iad, aac(60)-Ib, aac(60)-Ih, and aph(30)-VI.
c Determined using the multiplex PCR assay developed by Turton et al.10
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aminoglycosides, the resistance rates were 68.8% for gentamicin
and 37.5% for amikacin. All isolates were susceptible to colistin.
One isolate (isolate 14) was resistant to tigecycline.
3.3. Detection of resistance genes and resistance determinants
All isolates harbored blaOXA-23, blaOXA-51-like, and blaADC genes,
with one isolate also harboring blaNDM-1. One novel ADC, blaADC-57,
was designated with ﬁve amino acid substitutions (K150Q, S167P,
G242D, L253F, and R342G) in comparison to the ADC-1 protein. The
ISAba1 element was detected upstream of all blaOXA-23, blaADC-30, and
blaOXA-66 gene-harboring isolates. Eight isolates harbored armA, two
harbored aph(30)-VI, and one harbored both aac(60)-Ih and aph(30)-VI
(Table 1). Four different types of gene cassette were identiﬁed,
including two novel ones (arr-2-cmlA5 and aadB-aadA2-cmlA6-
aadA15). Each isolate had one integron gene cassette, except isolate
14 which had two cassettes. These integron cassette genes encoded
resistance to rifampin, chloramphenicol, and gentamicin (Figure 1).
3.4. Associations among clonality, antimicrobial susceptibility
proﬁles, and detected resistance determinants
Half of the study isolates were associated with the ECII lineage
(ECII isolates), while the other half were not (non-ECII isolates).
ECII isolates harbored the blaOXA-66 gene, which was carried with a
speciﬁc integron cassette arrangement (aacC1-orfX-orfX-orfX0-
aadA1). Non-ECII isolates all carried the arr-2-cmlA5 integron
cassette and armA (Figure 1), exhibited their clonality, and were
designated non-ECII clone. The blaNDM-1-positive isolate (isolate 1)
belonging to non-ECII clone and ST25, exhibited high-level
resistance to imipenem (MIC  512 mg/ml) and retained its
susceptibility to ampicillin/sulbactam, tigecycline, and colistin.
All non-ECII strains carrying armA were resistant to amikacin,
except two ST113 strains (isolate 12 and 13), which were
susceptible to this antimicrobial drug (Table 1).
4. Discussion
Different pulsotypes of our ECII CRAB isolates with dissimilar
antibiograms have been reported from South Africa,1 suggesting
that the ECII clone has been disseminated to and has perhaps
acquired carbapenem resistance in East Africa. Apart from three
European clonal complexes, the relationship with some other
novel genotypes in the global dissemination of CRAB has only
recently been addressed; only the ST25 clone has been suggested
to be well-established and highly associated with carbapenem
resistance.7 Three ST25 isolates (isolates 4, 5, and 6) from different
patients, belonging to the non-ECII clone and sharing an identical
PFGE pattern, were presumed to comprise a small-sized outbreak.
CRAB isolates in this study were susceptible to amikacin (50%) and
levoﬂoxacin (56.3%); these susceptibility rates are higher than those
reported in the global surveillance study (35.7% and 5.6%,
respectively).1 Although tigecycline has so far never been used in
East Africa, one ECII isolate exhibited resistance to tigecycline, which
is of concern.
Three carbapenem resistance gene structures were observed:
ISAba1-blaOXA-23, ISAba1-blaOXA-51-like, and blaNDM-1. ISAba1-blaOXA-
23 was the major carbapenem resistance mechanism found, as in
reports from other African countries.2,3An intriguing ﬁnding was the
identiﬁcation of an OXA-23 and NDM-1 co-producing extensively
drug-resistant A. baumannii (XDR-AB) isolate (isolate 1). This is the
ﬁrst report of NDM-1-encoded XDR-AB in East Africa. Previous
reports have shown NDM-1-producing bacteria mainly of the
Enterobacteriaceae species.4 In Kenya, we reported the ﬁrst isolations
of NDM-1 in K. pneumoniae.4 Whether the XDR-AB carrying NDM-1
was due to the horizontal transfer of the resistance gene by broad-
host plasmid needs further investigation. Three isolates (isolates 1, 2,
and 3) from the same patient shared an identical pulsotype. Isolate 1
was from the axilla and not from a respiratory-related sample,
indicating the nosocomial acquisition of NDM-1 from another
source or skin contact. As well as armA, isolate 1 also carried aac(60)-
Ih and aph(30)-VI, leading to high-level amikacin resistance (Table 1).
In conclusion, this study shows the emergence of the genetic
structure ISAba1-blaOXA-23, conferring carbapenem resistance in A.
baumannii in Kenya, in two distinct clonal lineages. One lineage is
linked to international clone ECII and the other is a newly identiﬁed
epidemic non-ECII clone carrying a novel integron cassette and the
ArmA gene. Remarkably, one ST25 CRAB isolate belonging to non-
ECII clone had acquired MBL NDM-1 and amikacin resistance
determinants, including armA, aac(60)-Ih, and aph(30)-VI. Highly
stringent control measures should be applied to prevent these
resistance genes spreading further into other bacterial species.
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Figure 1. Relationships between integron cassette genes, encoded resistance, and clonal lineages among carbapenem-resistant Acinetobacter baumannii isolates. Cassette
types (1–4) are arranged in order of integron PCR amplicon size. The open reading frames of the identiﬁed cassette gene are shown as arrows, with the direction of
transcription indicated by the arrowheads. Aminoglycoside resistance genes are shown as hatched arrows, rifampin resistance genes as ﬁlled arrows, chloramphenicol
resistance genes as gray arrows, and other identiﬁed genes as clear arrows. Clear rectangles indicate 50- and 30-conserved segments (CSs). The 50-CS and 30-CS ampliﬁcation
primers are indicated by ﬁlled arrowheads. GEN, gentamicin; SPT, spectinomycin; STR, streptomycin; RIF, rifampin; CHL, chloramphenicol.
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